UnitedHealth Group Inc. (NYSE:UNH) in association with Opturn has swung into action to lend its hand to the residents of Snohomish Country, Washington. The assistance is provided to those who have been impacted by the recent mudslide. United Health is reaching to the residents by providing free emotional support help line to them in the affected areas. UnitedHealth Group Inc. (NYSE:UNH) shares after opening at $81.48 moved to $82.30 on last trade day and at the end of the day closed at $81.54. Company price to sales ratio in past twelve months was calculated as 0.66 and price to cash ratio as 11.17. UnitedHealth Group Inc. (NYSE:UNH) showed a positive weekly performance of 1.98%.
Quest Diagnostics Inc. (NYSE:DGX) announced that it has entered into an agreement to acquire Summit Health – a leading provider of on-site prevention and wellness programs mainly for employees. Steve Rusckowski, President and CEO, Quest Diagnostics, stated “This acquisition supports Quest Diagnostics’ five-point strategy, which includes restoring growth and driving disciplined capital deployment. One of our capital deployment objectives is to grow one to two percent a year through strategically aligned, accretive acquisitions. Quest Diagnostics Inc (NYSE:DGX) shares advanced 5.55% in last trading session and ended the day on $57.99. DGX return on equity ratio is recorded as 28.00% and its return on assets is 12.30%. Quest Diagnostics Inc (NYSE:DGX) yearly performance is 3.42%.
Abbott Laboratories (NYSE:ABT) has earned an average rating of “Hold” from the nineteen ratings firms that are covering the company, AnalystRatings.Net reports. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company. Abbott Laboratories (NYSE:ABT) shares moved up 0.42% in last trading session and was closed at $ 38.56 while trading in range of $38.39 – $39.14. Abbott Laboratories (NYSE:ABT) year to date (YTD) performance is 0.60 %.
Bristol Myers Squibb Co. (NYSE:BMY)’s shares declined 1.96% to $51.04. The company on Mar. 24 announced that 12 abstracts have been accepted for presentation at The International Liver CongressTM, the 49th annual meeting of the European Association for the Study of the Liver (EASL), in London, April 9 – 13. Bristol-Myers Squibb is studying a broad portfolio of compounds in hopes of providing flexible treatment options to address the diverse unmet medical needs of a global HCV patient population. Bristol-Myers Squibb Co (NYSE:BMY) weekly performance is -3.80%. On last trading day company shares ended up $52.66. Bristol-Myers Squibb Co (NYSE:BMY) distance from 50-day simple moving average (SMA50) is -1.10%. Analysts mean target price for the company is $55.12.
Leave a Reply